Engineered multitargeting exosomes carrying miR-323a-3p for CRC therapy
Colorectal cancer (CRC) is in the forefront of malignancies for its high incidence and mortality. 5-Fluorouracil (5-FU) is one of the most widely used effective drugs for the treatment of CRC. However, there is an urgent need in reducing its systemic side effects and chemoresistance, in order to mak...
Uložené v:
| Vydané v: | International journal of biological macromolecules Ročník 247; s. 125794 |
|---|---|
| Hlavní autori: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Netherlands
Elsevier B.V
30.08.2023
|
| Predmet: | |
| ISSN: | 0141-8130, 1879-0003, 1879-0003 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Colorectal cancer (CRC) is in the forefront of malignancies for its high incidence and mortality. 5-Fluorouracil (5-FU) is one of the most widely used effective drugs for the treatment of CRC. However, there is an urgent need in reducing its systemic side effects and chemoresistance, in order to make 5-FU-based chemotherapy more effective in the treatment of CRC. In this study, engineered CRC cells were established to overexpress miR-323a-3p, which was a tumor suppressor that targeted both EGFR and TYMS. Then miR-323a-3p-loaded exosomes (miR-Exo) were obtained with suitable methods of collection and purification. We found that miR-Exo significantly inhibited CRC cell proliferation and induced apoptosis by the way of targeting EGFR directly in the cells, which eventually led to desirable tumor regression in the cell derived xenograft (CDX) and patient derived xenograft (PDX) tumor mice models. Moreover, we discovered that miR-323a-3p released from miR-Exo directly inhibited the upregulation of thymidylate synthase (TYMS) induced by 5-FU-resistence in CRC cells, resulting in the revival of tumor cytotoxicity from 5-FU. MiR-Exo could effectively induce the CRC cell apoptosis by targeting EGFR and TYMS, and enhance the therapeutic effects of 5-FU on CRC. Our work demonstrates the potency of miR-Exo for advanced CRC biotherapy. |
|---|---|
| AbstractList | Colorectal cancer (CRC) is in the forefront of malignancies for its high incidence and mortality. 5-Fluorouracil (5-FU) is one of the most widely used effective drugs for the treatment of CRC. However, there is an urgent need in reducing its systemic side effects and chemoresistance, in order to make 5-FU-based chemotherapy more effective in the treatment of CRC. In this study, engineered CRC cells were established to overexpress miR-323a-3p, which was a tumor suppressor that targeted both EGFR and TYMS. Then miR-323a-3p-loaded exosomes (miR-Exo) were obtained with suitable methods of collection and purification. We found that miR-Exo significantly inhibited CRC cell proliferation and induced apoptosis by the way of targeting EGFR directly in the cells, which eventually led to desirable tumor regression in the cell derived xenograft (CDX) and patient derived xenograft (PDX) tumor mice models. Moreover, we discovered that miR-323a-3p released from miR-Exo directly inhibited the upregulation of thymidylate synthase (TYMS) induced by 5-FU-resistence in CRC cells, resulting in the revival of tumor cytotoxicity from 5-FU. MiR-Exo could effectively induce the CRC cell apoptosis by targeting EGFR and TYMS, and enhance the therapeutic effects of 5-FU on CRC. Our work demonstrates the potency of miR-Exo for advanced CRC biotherapy. Colorectal cancer (CRC) is in the forefront of malignancies for its high incidence and mortality. 5-Fluorouracil (5-FU) is one of the most widely used effective drugs for the treatment of CRC. However, there is an urgent need in reducing its systemic side effects and chemoresistance, in order to make 5-FU-based chemotherapy more effective in the treatment of CRC. In this study, engineered CRC cells were established to overexpress miR-323a-3p, which was a tumor suppressor that targeted both EGFR and TYMS. Then miR-323a-3p-loaded exosomes (miR-Exo) were obtained with suitable methods of collection and purification. We found that miR-Exo significantly inhibited CRC cell proliferation and induced apoptosis by the way of targeting EGFR directly in the cells, which eventually led to desirable tumor regression in the cell derived xenograft (CDX) and patient derived xenograft (PDX) tumor mice models. Moreover, we discovered that miR-323a-3p released from miR-Exo directly inhibited the upregulation of thymidylate synthase (TYMS) induced by 5-FU-resistence in CRC cells, resulting in the revival of tumor cytotoxicity from 5-FU. MiR-Exo could effectively induce the CRC cell apoptosis by targeting EGFR and TYMS, and enhance the therapeutic effects of 5-FU on CRC. Our work demonstrates the potency of miR-Exo for advanced CRC biotherapy.Colorectal cancer (CRC) is in the forefront of malignancies for its high incidence and mortality. 5-Fluorouracil (5-FU) is one of the most widely used effective drugs for the treatment of CRC. However, there is an urgent need in reducing its systemic side effects and chemoresistance, in order to make 5-FU-based chemotherapy more effective in the treatment of CRC. In this study, engineered CRC cells were established to overexpress miR-323a-3p, which was a tumor suppressor that targeted both EGFR and TYMS. Then miR-323a-3p-loaded exosomes (miR-Exo) were obtained with suitable methods of collection and purification. We found that miR-Exo significantly inhibited CRC cell proliferation and induced apoptosis by the way of targeting EGFR directly in the cells, which eventually led to desirable tumor regression in the cell derived xenograft (CDX) and patient derived xenograft (PDX) tumor mice models. Moreover, we discovered that miR-323a-3p released from miR-Exo directly inhibited the upregulation of thymidylate synthase (TYMS) induced by 5-FU-resistence in CRC cells, resulting in the revival of tumor cytotoxicity from 5-FU. MiR-Exo could effectively induce the CRC cell apoptosis by targeting EGFR and TYMS, and enhance the therapeutic effects of 5-FU on CRC. Our work demonstrates the potency of miR-Exo for advanced CRC biotherapy. |
| ArticleNumber | 125794 |
| Author | Liu, Rui Pang, Yechun Wang, Yunfeng Hu, Jingying Liang, Shunshun Xu, Baiying Zhang, Yuanzhou Chen, Xingshi Luo, Xiaoying |
| Author_xml | – sequence: 1 givenname: Yechun surname: Pang fullname: Pang, Yechun organization: Department of General Surgery, Pudong New Area People's Hospital, China – sequence: 2 givenname: Xingshi surname: Chen fullname: Chen, Xingshi organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 3 givenname: Baiying surname: Xu fullname: Xu, Baiying organization: Department of General Surgery, Pudong New Area People's Hospital, China – sequence: 4 givenname: Yuanzhou surname: Zhang fullname: Zhang, Yuanzhou organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 5 givenname: Shunshun surname: Liang fullname: Liang, Shunshun organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 6 givenname: Jingying surname: Hu fullname: Hu, Jingying organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 7 givenname: Rui surname: Liu fullname: Liu, Rui email: liurui1510193@163.com organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 8 givenname: Xiaoying surname: Luo fullname: Luo, Xiaoying email: luoxy@shsci.org organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 9 givenname: Yunfeng surname: Wang fullname: Wang, Yunfeng email: wangyunfeng197911@163.com organization: Department of General Surgery, Pudong New Area People's Hospital, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37442504$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUtLAzEUhYMoWqt_QWbpZmoek0wGXCilPqAgFF2HTOampsxMapKK_fdOqd240dWFy3fOvZxzjo573wNCVwRPCCbiZjVxq9r5TpsJxZRNCOVlVRyhEZFllWOM2TEaYVKQXBKGz9B5jKthKziRp-iMlUVBOS5G6HHWL10PEKDJuk2bXNJhCcn1ywy-fPQdxMzoELa7TecWOaNM52ydWR-y6WKapXcIer29QCdWtxEuf-YYvT3MXqdP-fzl8Xl6P89NgUnKG1IxRjnTtYCm1rWhjRTMWl7VJautlFxKAZwxQqUQmEpLsS4HWltrtSjZGF3vfdfBf2wgJtW5aKBtdQ9-ExWVRSUrwrn4B8rkEAIeXhqjqx90U3fQqHVwnQ5bdchpAG73gAk-xgBWmSGp5HyfgnatIljtalErdahF7WpR-1oGufglP1z4U3i3F8KQ6aeDoKJx0BtoXACTVOPdXxbfvAypFQ |
| CitedBy_id | crossref_primary_10_1016_j_biopha_2025_118225 crossref_primary_10_1016_j_bioorg_2025_108343 crossref_primary_10_1016_j_tips_2024_02_006 crossref_primary_10_3390_cancers17132135 crossref_primary_10_2147_IJN_S498599 crossref_primary_10_1080_1061186X_2025_2535375 crossref_primary_10_3390_ijtm4020015 |
| Cites_doi | 10.1186/s13045-020-00987-y 10.1016/j.jconrel.2022.05.012 10.1186/s12943-020-01235-0 10.1016/j.redox.2021.102144 10.4251/wjgo.v15.i2.251 10.1016/j.jconrel.2022.06.011 10.1038/s41419-022-04709-9 10.1186/s12951-019-0517-8 10.1158/1078-0432.CCR-20-1219 10.1016/j.canlet.2019.10.016 10.1007/s10637-020-00930-5 10.1016/j.celrep.2022.111233 10.1186/s10020-022-00516-2 10.1111/cas.14718 10.1038/s41551-019-0485-1 10.1042/BSR20192847 10.1038/s41467-020-19173-2 10.3390/ijms21145028 10.7150/thno.73746 10.1053/j.gastro.2019.07.055 10.1016/S1470-2045(19)30862-9 10.1186/s12943-020-01297-0 10.1016/j.chembiol.2021.06.007 10.1016/j.biomaterials.2021.120784 10.1186/s13045-022-01358-5 10.1186/s12943-022-01671-0 10.1038/s41571-020-00445-1 10.7150/thno.52570 10.1016/j.arr.2020.101106 10.1080/19490976.2020.1854641 10.1158/1541-7786.MCR-18-0891 10.1080/19490976.2023.2186114 10.1002/adma.201904040 10.1021/acsnano.0c01676 10.1016/j.matbio.2022.11.005 10.1158/1535-7163.MCT-06-0419 10.1186/s12951-019-0563-2 10.1021/acsomega.1c06394 10.1016/j.pharmthera.2019.107447 10.7150/thno.41580 10.1016/j.devcel.2019.04.011 10.1111/cas.14532 10.1039/C5FO00120J 10.1016/j.cbi.2022.109938 10.1016/j.biomaterials.2020.120546 |
| ContentType | Journal Article |
| Copyright | 2023 Elsevier B.V. Copyright © 2023 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2023 Elsevier B.V. – notice: Copyright © 2023 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION NPM 7X8 7S9 L.6 |
| DOI | 10.1016/j.ijbiomac.2023.125794 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry |
| EISSN | 1879-0003 |
| ExternalDocumentID | 37442504 10_1016_j_ijbiomac_2023_125794 S0141813023026892 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO ABFRF ABGSF ABJNI ABMAC ABUDA ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADUVX AEBSH AEFWE AEHWI AEIPS AEKER AENEX AFJKZ AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU AXJTR BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KOM LX3 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SDP SES SPCBC SSH SSU SSZ T5K UNMZH ~02 ~G- 29J 9DU AAQXK AAYWO AAYXX ABFNM ABWVN ABXDB ACLOT ACRPL ACVFH ADCNI ADMUD ADNMO AEUPX AFPUW AGQPQ AGRDE AHHHB AIGII AIIUN AKBMS AKYEP APXCP ASPBG AVWKF AZFZN CITATION EFKBS EFLBG EJD FEDTE FGOYB G-2 HLW HVGLF HZ~ R2- SBG SEW UHS WUQ ~HD AFKWA AJOXV AMFUW NPM 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c401t-d1933253ab6edbabc2d863ff59b73bf885886e53312866028f20a7ab6afffa673 |
| ISICitedReferencesCount | 6 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001043055700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0141-8130 1879-0003 |
| IngestDate | Sun Sep 28 01:35:58 EDT 2025 Wed Oct 01 09:43:50 EDT 2025 Wed Feb 19 02:23:58 EST 2025 Sat Nov 29 07:24:57 EST 2025 Tue Nov 18 21:49:26 EST 2025 Sun Apr 06 06:53:33 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | 5-fluorouracil (5-FU)-resistance CRC therapy Exosomes TYMS miR-323a-3p EGFR |
| Language | English |
| License | Copyright © 2023 Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c401t-d1933253ab6edbabc2d863ff59b73bf885886e53312866028f20a7ab6afffa673 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 37442504 |
| PQID | 2838250019 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2849891556 proquest_miscellaneous_2838250019 pubmed_primary_37442504 crossref_citationtrail_10_1016_j_ijbiomac_2023_125794 crossref_primary_10_1016_j_ijbiomac_2023_125794 elsevier_sciencedirect_doi_10_1016_j_ijbiomac_2023_125794 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-08-30 |
| PublicationDateYYYYMMDD | 2023-08-30 |
| PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-30 day: 30 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | International journal of biological macromolecules |
| PublicationTitleAlternate | Int J Biol Macromol |
| PublicationYear | 2023 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | DeDecker, Coppedge, Avelar-Barragan, Karnes, Whiteson (bb0005) 2021; 13 Liang, Duan, Lu, Xia (bb0055) 2021; 11 Yang, Shi, Xie, Wang, Sun, Liu, Zhao, Zhao, Wang, Ma, Malkoc, Chiang, Deng, Chen, Fu, Kwak, Fan, Kang, Yin, Rhee, Bertani, Otero, Lu, Yun, Lee, Jiang, Teng, Kim, Lee (bb0100) 2020; 4 Blondy, David, Verdier, Mathonnet, Perraud, Christou (bb0200) 2020; 111 Tran, Xiang, Tran, Yin, Zhang, Kong, Chen, Sun, Li, Hou, Zhu, Duan (bb0050) 2020; 32 Zhang, Zhang, Yang, Tu, Huang, Wang, Chen, Pan, Chen (bb0170) 2022; 12 Zhou, Zhou, Chen, Ning, Chen, Guo, Zhang, Liu, Zhang, Li, Chu, Sun, Jiang (bb0115) 2021; 268 Bashyal, Thapa, Lee (bb0210) 2022; 348 Wortzel, Dror, Kenific, Lyden (bb0095) 2019; 49 Zhang, Song, Zhao, Yang, Chen, Liu, Ji, Zhu (bb0010) 2020; 470 Yang, Zhang, Zhang, Zhang, Chen, Ma, Larcher, Chen, Liu, Zhao, Tran, Chen, Veedu, Wang (bb0075) 2020; 10 Wang, Tang, Yang, Yin, Li, Hu, Tang, Ma, Zhang, Wang (bb0060) 2021; 273 Lu, Jin, Hou, Wu, Yu, Yao, Pan, Chang, Yu, Li, Li, Yan, Yan, Zhu, Liu, Su (bb0140) 2023; 115 Cremolini, Antoniotti, Rossini, Lonardi, Loupakis, Pietrantonio, Bordonaro, Latiano, Tamburini, Santini, Passardi, Marmorino, Grande, Aprile, Zaniboni, Murgioni, Granetto, Buonadonna, Moretto, Corallo, Cordio, Antonuzzo, Tomasello, Masi, Ronzoni, Di Donato, Carlomagno, Clavarezza, Ritorto, Mambrini, Roselli, Cupini, Mammoliti, Fenocchio, Corgna, Zagonel, Fontanini, Ugolini, Boni, Falcone (bb0035) 2020; 21 Gonda, Kabagwira, Senthil, Wall (bb0205) 2019; 17 Lee, Park, Jung, Kim, Jong, Kim, Bang (bb0215) 2006; 5 Cho, Ro, Yoon, Mizutani, Kang, Park, Il Kim, Clevers, Choi (bb0045) 2020; 11 Zhang, Liang, Xiao, Hu, Pang, Liu, Yang, Ao, Wei, Luo (bb0120) 2022; 13 Zhong, He, Wang, Hu, Huang, Zhao, Wei, Li (bb0015) 2022; 15 Rahmani, Saleki, Javanmehr, Khodaparast, Saadat, Nouri (bb0105) 2020; 62 Xu, Luo, Zhang, Li, Lee (bb0240) 2023; 15 Sharma, Joshi, Kindler (bb0130) 2020; 26 Yamamoto, Hayashi, Planchard, Morán, Gregorc, Dowell, Sakai, Yoh, Nishio, Cortot, Benhadji, Soni, Huang, Makris, Cedres (bb0150) 2020; 38 Yokogawa, Yano, Tsukioka, Osada, Wakasa, Ueno, Hoshino, Yamamura, Fujioka, Fukuoka, Ohkubo, Matsuo (bb0145) 2021; 112 Al Faruque, Choi, Kim, Kim (bb0065) 2022; 347 Guo, Yu, Sun, Zou, Liu, Huang (bb0040) 2021; 20 Kurasaka, Nishizawa, Ogino, Sato (bb0235) 2022; 7 Zhu, Sun, Wang, Huang, Zheng, Wang, Hu, Qin, Zou, Fu, Shen, Zhu, Geng, Lu, Jia, Qin, Dong (bb0080) 2020; 13 Aubets (bb0180) 2020; 21 Vázquez-Ríos, Molina-Crespo, Bouzo, López-López, Moreno-Bueno, de la Fuente (bb0125) 2019; 17 Pranzini, Pardella, Muccillo, Leo, Nesi, Santi, Parri, Zhang, Uribe, Lottini, Sabatino, Caselli, Arcangeli, Raugei, Colantuoni, Cirri, Chiarugi, Maddocks, Paoli, Taddei (bb0160) 2022; 40 Matuszyk (bb0220) 2022; 28 Siegel, Miller, Goding Sauer, Fedewa, Butterly, Anderson, Cercek, Smith, Jemal (bb0020) 2020; 70 Li, Zhang, Montgomery, Jiang, Lyon, Hu (bb0085) 2022; 18 Yang, Wu, Chen, Yang, Li, Tao, Wang, Sun, Zhang (bb0225) 2022; 360 Vodenkova, Buchler, Cervena, Veskrnova, Vodicka, Vymetalkova (bb0195) 2020; 206 Liang, Zhu, Ali, Tian, Xu, Si, Sun, Chen, Xiao (bb0165) 2020; 18 Olguin, Mendoza-Rodriguez, Sanchez-Barrera, Terrazas (bb0190) 2023; 15 Pawłowski, Szczęsny, Rempoła, Poznańska, Poznański (bb0155) 2019; 39 Yang, Song, Hwang, Choi, Song, Lim (bb0175) 2021; 47 Akimoto, Ugai, Zhong, Hamada, Fujiyoshi, Giannakis, Wu, Cao, Ng, Ogino (bb0030) 2021; 18 González-Sarrías, Tomé-Carneiro, Bellesia, Tomás-Barberán, Espín (bb0185) 2015; 6 Sridharan, Lim (bb0070) 2023; 19 Shang, Gu, Wang, Wang, Sun, Zeng, Chen, Chang, Ping, Ji, Wu, Quan, Yao, Zhou, Sun, Li (bb0110) 2020; 19 Han, Li, Hu, Gao, Zhai, Yang, Zhang (bb0090) 2022; 21 Stoffel, Murphy (bb0025) 2020; 158 Guo, Yu, Das, Huang (bb0135) 2020; 14 Liang, Bacanu, Sreekumar, Ramos, Dai, Michaelis, Cinatl, Seki, Cao, Coffill, Lane, Prabhu, Nordlund (bb0230) 2022; 29 Yokogawa (10.1016/j.ijbiomac.2023.125794_bb0145) 2021; 112 Zhang (10.1016/j.ijbiomac.2023.125794_bb0170) 2022; 12 Liang (10.1016/j.ijbiomac.2023.125794_bb0230) 2022; 29 Sharma (10.1016/j.ijbiomac.2023.125794_bb0130) 2020; 26 Zhang (10.1016/j.ijbiomac.2023.125794_bb0010) 2020; 470 Xu (10.1016/j.ijbiomac.2023.125794_bb0240) 2023; 15 Sridharan (10.1016/j.ijbiomac.2023.125794_bb0070) 2023; 19 Olguin (10.1016/j.ijbiomac.2023.125794_bb0190) 2023; 15 Akimoto (10.1016/j.ijbiomac.2023.125794_bb0030) 2021; 18 Rahmani (10.1016/j.ijbiomac.2023.125794_bb0105) 2020; 62 Han (10.1016/j.ijbiomac.2023.125794_bb0090) 2022; 21 Vodenkova (10.1016/j.ijbiomac.2023.125794_bb0195) 2020; 206 Li (10.1016/j.ijbiomac.2023.125794_bb0085) 2022; 18 Lu (10.1016/j.ijbiomac.2023.125794_bb0140) 2023; 115 Lee (10.1016/j.ijbiomac.2023.125794_bb0215) 2006; 5 Zhang (10.1016/j.ijbiomac.2023.125794_bb0120) 2022; 13 Shang (10.1016/j.ijbiomac.2023.125794_bb0110) 2020; 19 González-Sarrías (10.1016/j.ijbiomac.2023.125794_bb0185) 2015; 6 Wortzel (10.1016/j.ijbiomac.2023.125794_bb0095) 2019; 49 Yang (10.1016/j.ijbiomac.2023.125794_bb0175) 2021; 47 Guo (10.1016/j.ijbiomac.2023.125794_bb0135) 2020; 14 Zhong (10.1016/j.ijbiomac.2023.125794_bb0015) 2022; 15 Siegel (10.1016/j.ijbiomac.2023.125794_bb0020) 2020; 70 DeDecker (10.1016/j.ijbiomac.2023.125794_bb0005) 2021; 13 Al Faruque (10.1016/j.ijbiomac.2023.125794_bb0065) 2022; 347 Yang (10.1016/j.ijbiomac.2023.125794_bb0225) 2022; 360 Liang (10.1016/j.ijbiomac.2023.125794_bb0165) 2020; 18 Wang (10.1016/j.ijbiomac.2023.125794_bb0060) 2021; 273 Yamamoto (10.1016/j.ijbiomac.2023.125794_bb0150) 2020; 38 Blondy (10.1016/j.ijbiomac.2023.125794_bb0200) 2020; 111 Matuszyk (10.1016/j.ijbiomac.2023.125794_bb0220) 2022; 28 Guo (10.1016/j.ijbiomac.2023.125794_bb0040) 2021; 20 Pawłowski (10.1016/j.ijbiomac.2023.125794_bb0155) 2019; 39 Zhou (10.1016/j.ijbiomac.2023.125794_bb0115) 2021; 268 Aubets (10.1016/j.ijbiomac.2023.125794_bb0180) 2020; 21 Gonda (10.1016/j.ijbiomac.2023.125794_bb0205) 2019; 17 Bashyal (10.1016/j.ijbiomac.2023.125794_bb0210) 2022; 348 Liang (10.1016/j.ijbiomac.2023.125794_bb0055) 2021; 11 Cremolini (10.1016/j.ijbiomac.2023.125794_bb0035) 2020; 21 Zhu (10.1016/j.ijbiomac.2023.125794_bb0080) 2020; 13 Pranzini (10.1016/j.ijbiomac.2023.125794_bb0160) 2022; 40 Tran (10.1016/j.ijbiomac.2023.125794_bb0050) 2020; 32 Cho (10.1016/j.ijbiomac.2023.125794_bb0045) 2020; 11 Kurasaka (10.1016/j.ijbiomac.2023.125794_bb0235) 2022; 7 Yang (10.1016/j.ijbiomac.2023.125794_bb0075) 2020; 10 Stoffel (10.1016/j.ijbiomac.2023.125794_bb0025) 2020; 158 Yang (10.1016/j.ijbiomac.2023.125794_bb0100) 2020; 4 Vázquez-Ríos (10.1016/j.ijbiomac.2023.125794_bb0125) 2019; 17 |
| References_xml | – volume: 18 start-page: 230 year: 2021 end-page: 243 ident: bb0030 article-title: Rising incidence of early-onset colorectal cancer-a call to action publication-title: Nat. Rev. Clin. Oncol. – volume: 348 start-page: 723 year: 2022 end-page: 744 ident: bb0210 article-title: Recent progresses in exosome-based systems for targeted drug delivery to the brain publication-title: J. Control. Release – volume: 470 start-page: 84 year: 2020 end-page: 94 ident: bb0010 article-title: Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases publication-title: Cancer Lett. – volume: 17 start-page: 85 year: 2019 ident: bb0125 article-title: Exosome-mimetic nanoplatforms for targeted cancer drug delivery publication-title: J Nanobiotechnology. – volume: 10 start-page: 3684 year: 2020 end-page: 3707 ident: bb0075 article-title: Progress, opportunity, and perspective on exosome isolation-efforts for efficient exosome-based theranostics publication-title: Theranostics – volume: 18 year: 2022 ident: bb0085 article-title: Advanced technologies for molecular diagnosis of cancer: state of pre-clinical tumor-derived exosome liquid biopsies publication-title: Mater Today Bio. – volume: 15 start-page: 2186114 year: 2023 ident: bb0240 article-title: Therapeutic potential of publication-title: Gut Microbes – volume: 17 start-page: 337 year: 2019 end-page: 347 ident: bb0205 article-title: Internalization of exosomes through receptor-mediated endocytosis publication-title: Mol. Cancer Res. – volume: 11 start-page: 5321 year: 2020 ident: bb0045 article-title: 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation publication-title: Nat. Commun. – volume: 206 year: 2020 ident: bb0195 article-title: 5-Fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future publication-title: Pharmacol. Ther. – volume: 15 start-page: 160 year: 2022 ident: bb0015 article-title: Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications publication-title: J. Hematol. Oncol. – volume: 39 year: 2019 ident: bb0155 article-title: Combined in silico and 19F NMR analysis of 5-fluorouracil metabolism in yeast at low ATP conditions publication-title: Biosci. Rep. – volume: 115 start-page: 1 year: 2023 end-page: 15 ident: bb0140 article-title: Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer publication-title: Matrix Biol. – volume: 273 year: 2021 ident: bb0060 article-title: Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy publication-title: Biomaterials – volume: 268 year: 2021 ident: bb0115 article-title: Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment publication-title: Biomaterials – volume: 32 year: 2020 ident: bb0050 article-title: Exosomes and Nanoengineering: a match made for precision therapeutics publication-title: Adv. Mater. – volume: 21 start-page: 497 year: 2020 end-page: 507 ident: bb0035 article-title: GONO foundation investigators, upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial publication-title: Lancet Oncol. – volume: 21 start-page: 5028 year: 2020 ident: bb0180 article-title: J Félix a, Garavís M, Reyes L, Aviñó a, Eritja R, ciudad CJ, Noé V, detection of a G-Quadruplex as a regulatory element in publication-title: Int. J. Mol. Sci. – volume: 347 start-page: 330 year: 2022 end-page: 346 ident: bb0065 article-title: Enhanced effect of autologous EVs delivering paclitaxel in pancreatic cancer publication-title: J. Control. Release – volume: 360 year: 2022 ident: bb0225 article-title: Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase publication-title: Chem. Biol. Interact. – volume: 26 start-page: 3890 year: 2020 ident: bb0130 article-title: 5-FU, irinotecan, nab-paclitaxel in gastrointestinal cancers-response publication-title: Clin. Cancer Res. – volume: 62 year: 2020 ident: bb0105 article-title: Mesenchymal stem cell-derived extracellular vesicle-based therapies protect against coupled degeneration of the central nervous and vascular systems in stroke publication-title: Ageing Res. Rev. – volume: 6 start-page: 1460 year: 2015 end-page: 1469 ident: bb0185 article-title: The ellagic acid-derived gut microbiota metabolite, urolithin a, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells publication-title: Food Funct. – volume: 5 start-page: 3085 year: 2006 end-page: 3095 ident: bb0215 article-title: Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells publication-title: Mol. Cancer Ther. – volume: 20 start-page: 10 year: 2021 ident: bb0040 article-title: Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma publication-title: Mol. Cancer – volume: 14 start-page: 5075 year: 2020 end-page: 5089 ident: bb0135 article-title: Nano Codelivery of Oxaliplatin and Folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal Cancer and liver metastasis publication-title: ACS Nano – volume: 11 start-page: 3183 year: 2021 end-page: 3195 ident: bb0055 article-title: Engineering exosomes for targeted drug delivery publication-title: Theranostics – volume: 21 start-page: 207 year: 2022 ident: bb0090 article-title: Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer publication-title: Mol. Cancer – volume: 40 year: 2022 ident: bb0160 article-title: SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis publication-title: Cell Rep. – volume: 15 start-page: 251 year: 2023 end-page: 267 ident: bb0190 article-title: Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment? publication-title: World J Gastrointest Oncol. – volume: 13 start-page: 1854641 year: 2021 ident: bb0005 article-title: Microbiome distinctions between the CRC carcinogenic pathways publication-title: Gut Microbes – volume: 13 start-page: 152 year: 2020 ident: bb0080 article-title: Isolation and characterization of exosomes for cancer research publication-title: J. Hematol. Oncol. – volume: 19 start-page: 117 year: 2020 ident: bb0110 article-title: Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p-TGF-β1 axis publication-title: Mol. Cancer – volume: 28 start-page: 89 year: 2022 ident: bb0220 article-title: MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy publication-title: Mol. Med. – volume: 38 start-page: 1588 year: 2020 end-page: 1597 ident: bb0150 article-title: A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer publication-title: Investig. New Drugs – volume: 19 year: 2023 ident: bb0070 article-title: Exosomes and ultrasound: the future of theranostic applications publication-title: Mater Today Bio. – volume: 12 start-page: 4802 year: 2022 end-page: 4817 ident: bb0170 article-title: N publication-title: Theranostics – volume: 49 start-page: 347 year: 2019 end-page: 360 ident: bb0095 article-title: Exosome-mediated metastasis: communication from a distance publication-title: Dev. Cell – volume: 18 start-page: 10 year: 2020 ident: bb0165 article-title: Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer publication-title: J Nanobiotechnology – volume: 13 start-page: 256 year: 2022 ident: bb0120 article-title: MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer publication-title: Cell Death Dis. – volume: 47 year: 2021 ident: bb0175 article-title: Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells publication-title: Redox Biol. – volume: 112 start-page: 422 year: 2021 end-page: 432 ident: bb0145 article-title: dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA-repair-defective human cancer cells publication-title: Cancer Sci. – volume: 111 start-page: 3142 year: 2020 end-page: 3154 ident: bb0200 article-title: 5-fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes publication-title: Cancer Sci. – volume: 4 start-page: 69 year: 2020 end-page: 83 ident: bb0100 article-title: Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation publication-title: Nat Biomed Eng. – volume: 158 start-page: 341 year: 2020 end-page: 353 ident: bb0025 article-title: Epidemiology and mechanisms of the increasing incidence of Colon and Rectal cancers in young adults publication-title: Gastroenterology – volume: 70 start-page: 145 year: 2020 end-page: 164 ident: bb0020 article-title: Colorectal cancer statistics, 2020 publication-title: CA Cancer J. Clin. – volume: 29 start-page: 572 year: 2022 end-page: 585.e8 ident: bb0230 article-title: CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity publication-title: Cell Chem Biol. – volume: 7 start-page: 6046 year: 2022 end-page: 6052 ident: bb0235 article-title: Trapping of 5-fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil publication-title: ACS Omega. – volume: 13 start-page: 152 issue: 1 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0080 article-title: Isolation and characterization of exosomes for cancer research publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-020-00987-y – volume: 347 start-page: 330 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0065 article-title: Enhanced effect of autologous EVs delivering paclitaxel in pancreatic cancer publication-title: J. Control. Release doi: 10.1016/j.jconrel.2022.05.012 – volume: 19 start-page: 117 issue: 1 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0110 article-title: Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p-TGF-β1 axis publication-title: Mol. Cancer doi: 10.1186/s12943-020-01235-0 – volume: 47 year: 2021 ident: 10.1016/j.ijbiomac.2023.125794_bb0175 article-title: Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells publication-title: Redox Biol. doi: 10.1016/j.redox.2021.102144 – volume: 15 start-page: 251 issue: 2 year: 2023 ident: 10.1016/j.ijbiomac.2023.125794_bb0190 article-title: Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment? publication-title: World J Gastrointest Oncol. doi: 10.4251/wjgo.v15.i2.251 – volume: 18 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0085 article-title: Advanced technologies for molecular diagnosis of cancer: state of pre-clinical tumor-derived exosome liquid biopsies publication-title: Mater Today Bio. – volume: 348 start-page: 723 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0210 article-title: Recent progresses in exosome-based systems for targeted drug delivery to the brain publication-title: J. Control. Release doi: 10.1016/j.jconrel.2022.06.011 – volume: 13 start-page: 256 issue: 3 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0120 article-title: MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer publication-title: Cell Death Dis. doi: 10.1038/s41419-022-04709-9 – volume: 17 start-page: 85 issue: 1 year: 2019 ident: 10.1016/j.ijbiomac.2023.125794_bb0125 article-title: Exosome-mimetic nanoplatforms for targeted cancer drug delivery publication-title: J Nanobiotechnology. doi: 10.1186/s12951-019-0517-8 – volume: 26 start-page: 3890 issue: 14 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0130 article-title: 5-FU, irinotecan, nab-paclitaxel in gastrointestinal cancers-response publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-1219 – volume: 470 start-page: 84 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0010 article-title: Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases publication-title: Cancer Lett. doi: 10.1016/j.canlet.2019.10.016 – volume: 38 start-page: 1588 issue: 5 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0150 article-title: A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer publication-title: Investig. New Drugs doi: 10.1007/s10637-020-00930-5 – volume: 40 issue: 7 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0160 article-title: SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis publication-title: Cell Rep. doi: 10.1016/j.celrep.2022.111233 – volume: 28 start-page: 89 issue: 1 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0220 article-title: MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy publication-title: Mol. Med. doi: 10.1186/s10020-022-00516-2 – volume: 112 start-page: 422 issue: 1 year: 2021 ident: 10.1016/j.ijbiomac.2023.125794_bb0145 article-title: dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA-repair-defective human cancer cells publication-title: Cancer Sci. doi: 10.1111/cas.14718 – volume: 4 start-page: 69 issue: 1 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0100 article-title: Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation publication-title: Nat Biomed Eng. doi: 10.1038/s41551-019-0485-1 – volume: 39 issue: 12 year: 2019 ident: 10.1016/j.ijbiomac.2023.125794_bb0155 article-title: Combined in silico and 19F NMR analysis of 5-fluorouracil metabolism in yeast at low ATP conditions publication-title: Biosci. Rep. doi: 10.1042/BSR20192847 – volume: 11 start-page: 5321 issue: 1 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0045 article-title: 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation publication-title: Nat. Commun. doi: 10.1038/s41467-020-19173-2 – volume: 21 start-page: 5028 issue: 14 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0180 article-title: J Félix a, Garavís M, Reyes L, Aviñó a, Eritja R, ciudad CJ, Noé V, detection of a G-Quadruplex as a regulatory element in thymidylate synthase for gene silencing using Polypurine reverse Hoogsteen hairpins publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms21145028 – volume: 12 start-page: 4802 issue: 10 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0170 article-title: N6-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming publication-title: Theranostics doi: 10.7150/thno.73746 – volume: 158 start-page: 341 issue: 2 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0025 article-title: Epidemiology and mechanisms of the increasing incidence of Colon and Rectal cancers in young adults publication-title: Gastroenterology doi: 10.1053/j.gastro.2019.07.055 – volume: 70 start-page: 145 issue: 3 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0020 article-title: Colorectal cancer statistics, 2020 publication-title: CA Cancer J. Clin. – volume: 21 start-page: 497 issue: 4 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0035 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30862-9 – volume: 20 start-page: 10 issue: 1 year: 2021 ident: 10.1016/j.ijbiomac.2023.125794_bb0040 article-title: Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma publication-title: Mol. Cancer doi: 10.1186/s12943-020-01297-0 – volume: 29 start-page: 572 issue: 4 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0230 article-title: CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity publication-title: Cell Chem Biol. doi: 10.1016/j.chembiol.2021.06.007 – volume: 273 year: 2021 ident: 10.1016/j.ijbiomac.2023.125794_bb0060 article-title: Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy publication-title: Biomaterials doi: 10.1016/j.biomaterials.2021.120784 – volume: 15 start-page: 160 issue: 1 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0015 article-title: Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-022-01358-5 – volume: 21 start-page: 207 issue: 1 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0090 article-title: Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer publication-title: Mol. Cancer doi: 10.1186/s12943-022-01671-0 – volume: 18 start-page: 230 issue: 4 year: 2021 ident: 10.1016/j.ijbiomac.2023.125794_bb0030 article-title: Rising incidence of early-onset colorectal cancer-a call to action publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-00445-1 – volume: 11 start-page: 3183 issue: 7 year: 2021 ident: 10.1016/j.ijbiomac.2023.125794_bb0055 article-title: Engineering exosomes for targeted drug delivery publication-title: Theranostics doi: 10.7150/thno.52570 – volume: 62 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0105 article-title: Mesenchymal stem cell-derived extracellular vesicle-based therapies protect against coupled degeneration of the central nervous and vascular systems in stroke publication-title: Ageing Res. Rev. doi: 10.1016/j.arr.2020.101106 – volume: 13 start-page: 1854641 issue: 1 year: 2021 ident: 10.1016/j.ijbiomac.2023.125794_bb0005 article-title: Microbiome distinctions between the CRC carcinogenic pathways publication-title: Gut Microbes doi: 10.1080/19490976.2020.1854641 – volume: 19 year: 2023 ident: 10.1016/j.ijbiomac.2023.125794_bb0070 article-title: Exosomes and ultrasound: the future of theranostic applications publication-title: Mater Today Bio. – volume: 17 start-page: 337 issue: 2 year: 2019 ident: 10.1016/j.ijbiomac.2023.125794_bb0205 article-title: Internalization of exosomes through receptor-mediated endocytosis publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-18-0891 – volume: 15 start-page: 2186114 issue: 1 year: 2023 ident: 10.1016/j.ijbiomac.2023.125794_bb0240 article-title: Therapeutic potential of clostridium butyricum anticancer effects in colorectal cancer publication-title: Gut Microbes doi: 10.1080/19490976.2023.2186114 – volume: 32 issue: 18 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0050 article-title: Exosomes and Nanoengineering: a match made for precision therapeutics publication-title: Adv. Mater. doi: 10.1002/adma.201904040 – volume: 14 start-page: 5075 issue: 4 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0135 article-title: Nano Codelivery of Oxaliplatin and Folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal Cancer and liver metastasis publication-title: ACS Nano doi: 10.1021/acsnano.0c01676 – volume: 115 start-page: 1 year: 2023 ident: 10.1016/j.ijbiomac.2023.125794_bb0140 article-title: Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer publication-title: Matrix Biol. doi: 10.1016/j.matbio.2022.11.005 – volume: 5 start-page: 3085 issue: 12 year: 2006 ident: 10.1016/j.ijbiomac.2023.125794_bb0215 article-title: Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-06-0419 – volume: 18 start-page: 10 issue: 1 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0165 article-title: Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer publication-title: J Nanobiotechnology doi: 10.1186/s12951-019-0563-2 – volume: 7 start-page: 6046 issue: 7 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0235 article-title: Trapping of 5-fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil publication-title: ACS Omega. doi: 10.1021/acsomega.1c06394 – volume: 206 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0195 article-title: 5-Fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2019.107447 – volume: 10 start-page: 3684 issue: 8 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0075 article-title: Progress, opportunity, and perspective on exosome isolation-efforts for efficient exosome-based theranostics publication-title: Theranostics doi: 10.7150/thno.41580 – volume: 49 start-page: 347 issue: 3 year: 2019 ident: 10.1016/j.ijbiomac.2023.125794_bb0095 article-title: Exosome-mediated metastasis: communication from a distance publication-title: Dev. Cell doi: 10.1016/j.devcel.2019.04.011 – volume: 111 start-page: 3142 issue: 9 year: 2020 ident: 10.1016/j.ijbiomac.2023.125794_bb0200 article-title: 5-fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes publication-title: Cancer Sci. doi: 10.1111/cas.14532 – volume: 6 start-page: 1460 issue: 5 year: 2015 ident: 10.1016/j.ijbiomac.2023.125794_bb0185 article-title: The ellagic acid-derived gut microbiota metabolite, urolithin a, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells publication-title: Food Funct. doi: 10.1039/C5FO00120J – volume: 360 year: 2022 ident: 10.1016/j.ijbiomac.2023.125794_bb0225 article-title: Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase publication-title: Chem. Biol. Interact. doi: 10.1016/j.cbi.2022.109938 – volume: 268 year: 2021 ident: 10.1016/j.ijbiomac.2023.125794_bb0115 article-title: Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment publication-title: Biomaterials doi: 10.1016/j.biomaterials.2020.120546 |
| SSID | ssj0006518 |
| Score | 2.4173605 |
| Snippet | Colorectal cancer (CRC) is in the forefront of malignancies for its high incidence and mortality. 5-Fluorouracil (5-FU) is one of the most widely used... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 125794 |
| SubjectTerms | 5-fluorouracil (5-FU)-resistance apoptosis cell proliferation colorectal neoplasms CRC therapy cytotoxicity drug therapy EGFR Exosomes fluorouracil miR-323a-3p mortality patients remission thymidylate synthase TYMS xenotransplantation |
| Title | Engineered multitargeting exosomes carrying miR-323a-3p for CRC therapy |
| URI | https://dx.doi.org/10.1016/j.ijbiomac.2023.125794 https://www.ncbi.nlm.nih.gov/pubmed/37442504 https://www.proquest.com/docview/2838250019 https://www.proquest.com/docview/2849891556 |
| Volume | 247 |
| WOSCitedRecordID | wos001043055700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-0003 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006518 issn: 0141-8130 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFLW6DcFeEN8U2BQk3lBGiRvbeZyisYHQNE1Dyp4sJ7HVVGtStU1V_j3XdpwEjW7wwEtUJXFb-ZzY597cD4Q-pPDMKBKkvhqR1B-HjPgsJ8QnBOywUapNEpMo_J2en7MkiS4Gg7XLhVnf0LJkm000_69QwzkAW6fO_gPc7ZfCCfgMoMMRYIfjXwHvKgyCkjTRgjbWW3sE5KZaVro4UyYWC5PeNCsufRxg4eO5iTeML-OPq16dgWkX5965DXvFJmwJJ4PzTJjIPtNst4tLvGjc0dcym9QtD-MmJSTRbvpJ4U4ntX0DUvx0-2nfo31dg4ydVHXfTxFg43i1r1ykXVsZjXQSO-4vvoGtt9ksn6C2qO15fGtlt06G6VEx1XUJhK4-GeCj2wMAjPnMQIvpeKwLtHU7XRt_6C7toL2AhhEs6HvHX0-Sb-0eTsLPrJdP_uef3UcP3RdtUzXbrBajXq6eoMeN2eEdW7o8RQNZPkOPYtft7zk67Wjj_U4bz9HGc7TxerTxgDYe0MZraPMC_fhychWf-U2TDT8D03rl56DgcRBikRKZpyLNgpwRrFQYpRSnirGQMSLBKAAhQwioURWMBIW7hVJKEIpfot2yKuVr5AmQ5gzMfamIaWwXSdgdVA42SRRSQfMhCt0k8aypQK8bodxwF2o45W6euZ5nbud5iD614-a2Bsu9IyKHAW-UpFWIHOh079j3DjQOGOj3Z6KUVb3koMQZgA1G0V33jCOmey6QIXplEW__syPLm61X3qL97tF5h3ZXi1oeoAfZelUsF4dohybssKHqL164sCM |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Engineered+multitargeting+exosomes+carrying+miR-323a-3p+for+CRC+therapy&rft.jtitle=International+journal+of+biological+macromolecules&rft.au=Pang%2C+Yechun&rft.au=Chen%2C+Xingshi&rft.au=Xu%2C+Baiying&rft.au=Zhang%2C+Yuanzhou&rft.date=2023-08-30&rft.eissn=1879-0003&rft.volume=247&rft.spage=125794&rft_id=info:doi/10.1016%2Fj.ijbiomac.2023.125794&rft_id=info%3Apmid%2F37442504&rft.externalDocID=37442504 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0141-8130&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0141-8130&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0141-8130&client=summon |